Exonate Limited
Cambridge Science Park, Unit 23
Milton Road
Cambridge
CB4 0EY
United Kingdom
Tel: 0115-823-1135
Website: http://exonate.com/
About Exonate Limited
Exonate Limited was founded in 2013 and is based in Nottingham and Cambridge in the UK. Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis), which is a key driver of disease progression in ophthalmic conditions and cancer Exonate’s founders have identified and generated a novel class of drugs, “SPHINXes,” that modulate alternative mRNA splicing. We have developed a pipeline of molecules that promise therapeutics for anti-angiogenic therapies in ophthalmology, oncology, analgesia, diabetes, neurodegeneration and renal disease.YEAR FOUNDED:
2013
LEADERSHIP:
CEO: Dr. Catherine Beech MB ChB OBE
CSO: Professor David Bates
Medical Director: Professor Steven J. Harper
Founding Scientist: Dr. Lucy Donaldson
CAREER:
Please click here for Exonate's job opportunities.
TECHNOLOGY:
Please click here for Exonate's technology.
5 articles about Exonate Limited
-
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
3/5/2024
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the data from a successful Phase Ib/IIa trial for lead candidate EXN407.
-
Exonate announces the initiation of Phase Ib/II clinical trial for Diabetic Macular Oedema, as part of its collaboration with JanssenFirst patient dosed with an investigational retinal vascular disease eye drop
2/2/2021
Exonate, an mRNA therapy company focused on retinal diseases, announced that in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the first patient has been dosed with Exonate's lead compound, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema.
-
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)
1/13/2020
The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss.
-
Exonate Receives Wellcome Trust Funding To Develop Eye Drop Treatment For Wet Age-Related Macular Degeneration (Wet AMD)
2/6/2017
-
Exonate Closes Successful Funding Round - To Develop Eye Drops Treatment For Wet Age-related Macular Degeneration (Wet AMD)
12/1/2016